Canada: Food, Drugs, Healthcare, Life Sciences

On March 18, 2025, Health Canada released a Notice that it is seeking feedback on a draft guidance on co-packaged drug products.

On March 25, 2025, Canada's Drug Agency published its annual Watch List, which identifies technologies with the most potential to transform health systems and shape the future of health care in Canada.

Health Canada is seeking stakeholder consultation for a proposed framework that would allow Canadians to access cannabidiol (CBD) containing health products without a prescription

On March 18, 2025, Health Canada released a Notice that it is seeking feedback on a draft guidance on co-packaged drug products.

On March 25, 2025, Canada's Drug Agency published its annual Watch List, which identifies technologies with the most potential to transform health systems and shape the future of health care in Canada.

On April 16, 2025, the Government of Canada issued the "United States Surtax Remission Order (2025)" (the "Remission Order") pursuant to section 115 of the Customs Tariff, which was followed by the release of a customs notice on the application of the Remission Order (the "Customs Notice") by the Canada Border Services Agency.

On March 18, 2025, Health Canada released a Notice that it is seeking feedback on a draft guidance on co-packaged drug products.

On March 25, 2025, Canada's Drug Agency published its annual Watch List, which identifies technologies with the most potential to transform health systems and shape the future of health care in Canada.

A recent Privacy Complaint (MR21-00090) before the Information and Privacy Commissioner of Ontario (IPC) expanded the scope of what will be considered a privacy breach for Ontario public sector bodies.

On June 8, 2012, Genentech’s lawsuit seeking a declaration that US Patent No. 6,733,752 was invalid and not-infringed by Genentech’s trastuzumab product (HERCEPTIN).

Health Canada specifically contemplates certain proteins as SEBs in its Guidance, although Health Canada has not limited SEBs to only particular classes of drugs.

On May 23, 2012, the Federal Court held that Merck Frosst Canada Ltd. ("Merck") is liable to Apotex Inc. ("Apotex") for damages under section 8 of the Patented Medicines (Notice of Compliance) Regulations (the "Regulations"), but exercised its discretion to reduce the amount of compensation payable based on a defence of ex turpi causa.